NCT04588285View on ClinicalTrials.gov

Ambroxol in New and Early DLB, A Phase IIa Multicentre Randomized Controlled Double Blind Clinical Trial

PHASE2RecruitingINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

May 4, 2021

Primary Completion Date

December 1, 2024

Study Completion Date

July 1, 2025

Conditions
Dementia With Lewy Bodies
Interventions
DRUG

Ambroxol

Oral ambroxol medication (60 mg) from day 1 to study end (at 60 mg TID (day 1-7), 120 mg TID (day 8- 14), 315 mg BID (day 15-21), 315 mg TID (day 22-28) and 420 mg TID (day 29-550)

DRUG

Placebo

Oral placebo medication (60 mg) from day 1 to study end (at 60 mg TID (day 1-7), 120 mg TID (day 8- 14), 315 mg BID (day 15-21), 315 mg TID (day 22-28) and 420 mg TID (day 29-550)

Trial Locations (1)

5504

RECRUITING

Helse Fonna, Haugesund

All Listed Sponsors
collaborator

Klinbeforsk

OTHER

collaborator

Helse-Bergen HF

OTHER

lead

Helse Fonna

OTHER